Bromocriptine induced pleuropulmonary fibrosis.

Abstract

Bromocriptine is an ergot derivative with dopaminergic properties that is of value in the treatment of Parkinsonism. The development of pleuropulmonary fibrosis during treat- ment with bromocriptine has been reported,' 4 but a causal relationship has been questioned.5 6 We describe a patient who developed a systemic illness, including pleuro- pulmonary fibrosis, during treatment with bromocriptine for Parkinsonism, and in whom cessation of the drug was followed by weight gain, reversal of anaemia, a fall in the raised serum IgG concentration and erythrocyte sedimentation rate, and disappearance of neutrophil leucocytosis in lung lavage fluid, strongly supporting a causal relationship with bromocriptine.